Based on 7 analysts giving stock ratings to Lineage Cell Therapeutics Inc in the past month.
In the current month, LCTX has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. LCTX average Analyst price target in the last month is 5.500.
Based on analysts' estimates, LCTX EPS is projected to reach -0.004 in FY2026Q4, following reported EPS of 0.017 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD 0.02, while Lineage Cell Therapeutics IncLCTX's earnings per share (EPS) for the previous quarter was USD 0.01. EPS for the next quarter is expected at USD -0.00.